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Background: Folate and iron deficiency during pregnancy are risk factors for anaemia, preterm delivery, and low
birth weight, and may contribute to poor neonatal health and increased maternal mortality. The World Health
Organization recommends supplementation of folic acid (FA) and iron for all pregnant women at risk of
malnutrition to prevent anaemia. We assessed the use of prenatal folic acid and iron supplementation among
women in a geographical area with a high prevalence of anaemia, in relation to socio-demographic, morbidity and
health services utilization factors.
Methods: We analysed a cohort of 21,889 women who delivered at Kilimanjaro Christian Medical Centre (KCMC),
Moshi, Tanzania, between 1999 and 2008. Logistic regression models were used to describe patterns of reported
intake of prenatal FA and iron supplements.
Results: Prenatal intake of FA and iron supplements was reported by 17.2% and 22.3% of pregnant women,
respectively. Sixteen percent of women reported intake of both FA and iron. Factors positively associated with FA
supplementation were advanced maternal age (OR = 1.17, 1.02-1.34), unknown HIV status (OR = 1.54, 1.42-1.67), a
diagnosis of anaemia during pregnancy (OR = 12.03, 9.66-14.98) and indicators of lower socioeconomic status.
Women were less likely to take these supplements if they reported having had a malaria episode before (OR = 0.57,
0.53-0.62) or during pregnancy (OR = 0.45, 0.41-0.51), reported having contracted other infectious diseases
(OR = 0.45, 0.42-0.49), were multiparous (OR = 0.73, 0.66-0.80), had preeclampsia/eclampsia (OR = 0.48, 0.38-0.61), or
other diseases (OR = 0.55, 0.44-0.69) during pregnancy. Similar patterns of association emerged when iron
supplementation alone and supplementation with both iron and FA were evaluated.
Conclusions: FA and iron supplementation are low among pregnant women in Northern Tanzania, in particular
among women with co-morbidities before or during pregnancy. Attempts should be made to increase
supplementation both in general and among women with pregnancy complications.
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Folate deficiency at conception and in early pregnancy is
associated with increased risk of neural tube defects [1,2].
In both developing and developed countries, supplemen-
tation with 400 micrograms per day (μg/d) of folic acid is
recommended for all women of child-bearing age [3,4].
Whereas men generally have iron homeostasis even in set-
tings where dietary iron is low, in women both before
pregnancy due to blood loss resulting from menses and
during pregnancy, the body’s capacity to upregulate iron
absorption is often insufficient [5]. The use of prophylactic
iron supplements among pregnant women in developed
countries is controversial, as the benefits of such supple-
mentation in the absence of anaemia have not been firmly
established [6,7]. However, the current WHO guidelines
recommend that all pregnant women in areas where an-
aemia is highly prevalent receive supplements of both iron
and folic acid [4]. Both folate and iron deficiency during
pregnancy are risk factors for anaemia, preterm delivery,
and low birth weight, and may contribute to poor neo-
natal health and increased maternal mortality [4,8,9].
There is very little data on the prevalence of neural
tube defects at birth in Tanzania, and the primary indi-
cation for both folic acid and iron supplementation in
this population is the prevention or treatment of an-
aemia during pregnancy. Folic acid and iron supplemen-
tation in this population has also been linked to reduced
risk of hypertension in HIV positive pregnant women
and malaria in their offspring [10,11]. The most recent
country wide data from Tanzania on the prevalence of
anaemia in pregnancy indicates that as many as 58% of
Tanzanian women are anaemic during pregnancy [12].
In 20% anaemia was severe (Hb< 8.5 g/dl) enough to re-
quire a referral [13]. A study from rural Tanzania
showed that about 60% of pregnant women had depleted
iron stores and that anemia in pregnancy was associated
with markers of infection and other nutritional deficien-
cies [14].
Recommendations for iron and folic acid in pregnancy
in Tanzania follow the World Health Organization
(WHO) recommendations of 60 milligrams (mg) of iron
in addition to folic acid daily for all pregnant women at
risk of malnutrition to prevent anaemia [4]. The strong
evidence supporting folic acid supplementation during
pregnancy, emphasized in the WHO iron guidelines,
have led to wide prescription of folic acid and iron pre-
conceptionally and prenatally in developing countries
[15]. However, adherence to supplementation varies
greatly and is influenced by socio-demographic and
health factors [16-21]. In this study, we explore how folic
acid and iron supplementation during pregnancy in
Northern Tanzania corresponds with the recommenda-
tions, and to assess the extent to which socio-
demographic indicators, health before or duringpregnancy, or health care factors are associated with
such supplementation.
Methods
Study population
In this hospital based cross-sectional observational study
we utilize data from the Kilimanjaro Christian Medical
College (KCMC). The hospital is one of four zonal refer-
ral hospitals in Tanzania. It serves the local community
and receives medical referrals from the larger Kiliman-
jaro region (population ~10 million). Most patients are
indigenous Chagga and Pare, although over 60 other
ethnic groups including Sambaa, Sukuma, Rangi and
Maasai are also represented [22].
Births occurring at KCMC after 1999 have been elec-
tronically recorded in a birth registry housed at KCMC.
Methods for recruiting participants for this registry have
been described in detail elsewhere [22]. Briefly, the birth
registry is part of a collaboration between the University
of Bergen, Norway and the KCMC, Tumaini University
in Moshi Urban District of the Kilimanjaro region in
Northern Tanzania. Women admitted for delivery are
asked to bring a copy of their antenatal care (ANC) card,
a medical record of visits during pregnancy. Within 24
hours of delivery and after maternal verbal consent, a
registry midwife conducts a structured interview with
the mother and abstracts information on antenatal visits
for the medical record. The registry combines ANC data
and pregnancy outcomes data.
From February 1st 1999 to December 31st 2008, 26,152
births were included in the birth registry. We excluded
referrals due to pregnancy or labour complications
(n= 3,582) as they generally do not receive antenatal care
at KCMC. To ensure that each pregnancy was counted
only once since our unit of analysis was the pregnancy
and not the birth, we excluded second twins and second
and third triplets (n= 851), leaving 21,889 pregnancies in
the analyses sample. Each pregnancy was included as a
separate observation for women who delivered more than
once during the 10 year period. The overall registry study
was approved by the KCMC Ethics Committee and the
Ministry of Health in Tanzania. The protocol for the
current analyses was approved by the Duke University
Medical Center Institutional Review Board.
Description of variables
Folic acid and iron supplementation
Information on folic acid and iron was retrieved from
the antenatal record where there are separate check-
boxes for folic acid and iron supplementation. Informa-
tion was further obtained by interview with responses
“Yes” or “No” to the questions “Did you take any drugs
during this pregnancy?” The questions allowed women
to report intake of these supplements whether they were
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practice, or purchased over the counter from somewhere
else than the KCMC pharmacy. Neither supplementation
dose nor timing of when supplementation began, were
collected. Supplementation of folic acid and iron were
treated as binary outcomes in all analyses.
Socio-demographic correlates of supplementation
Socio-demographic correlates of supplement use included
marital status (married, single, divorced, widowed); ma-
ternal age in years (<18, 18–25, 26–35,>35); parity
(nulliparous, parous); education level of the woman and
her partner (none, primary (1–7 years), secondary
(8–11 years), tertiary (12 or more years)); occupation in
categories of professional denoting requiring training
(teachers, doctors, nurses, midwives and other occupa-
tions normally requiring education beyond secondary
school level), housewife (housework, care of offspring),
farmer (plant or animal husbandry in family farm in
addition to housework and caring for offspring), service
(typically, ward attendant in hospital, cleaner, bus driver,
shopkeeper and messenger), business (denotes shop own-
ers or women who conduct other trades, with measurable
incomes), and other (including students, hairdressers, or
house-girls) and tribe of participant and her partner cate-
gorized as Chagga, Pare and other. To avoid many and
small categories in the multiple regression analysis, we
grouped some of the categories for maternal age, parental
education and parental occupation.
Health indicators and healthcare utilization
Health indicators based on structured interview with the
mother and with supplementary information from the
antenatal record and standard protocols were episodes of
malaria, anaemia, or infections. Infections were defined as
any infectious condition other than schistosomiasis, tuber-
culosis, or malaria. “Other diseases before pregnancy”
included diabetes, heart disease, epilepsy, liver disease,
sickle cell, TB, and lung disease. “Other diseases during
pregnancy” included gestational diabetes, tuberculosis,
diabetes, hypertension, epilepsy, bleeding, jaundice, schis-
tosomiasis, heart disease and lung disease. Health care
utilization variables included number of prenatal care vis-
its categorized into few or no visits (0–1), 2–3 visits, 4–8
visits (recommended number of visits in uncomplicated
pregnancies [12], and 9–15 visits (more frequent than
once a month), as well as knowledge of HIV infection sta-
tus. The diagnosis of anaemia was based on haemoglobin
levels below 8.5 grams per decilitre at any time during
pregnancy.
Statistical analyses
We estimated the proportion of women who ever used
folic acid (yes/no), iron (yes/no) or both supplements(yes/no) during the prenatal period (percentages and
95% confidence intervals). Contingency tables were
employed to estimate crude odds ratios (ORs) with 95%
confidence intervals for the association between each of
the three dichotomous outcome variables, and socio-
demographic, health services utilization and pre-
pregnancy and pregnancy related morbidity. All factors
associated with iron or folic acid supplementation in bi-
variate analyses (defined as p value ≤ 0.20) were included
in a multiple logistic regression model to identify those
independently associated with supplementation. Due to
missing values, the number of observations in the mul-
tiple regression analysis was 21,027 (862 observations
had missing values in one or more variables). All analyt-
ical tests were carried out using STATA/IC 10.1™ and
SPSS 18.0 for Windows (SPSS Inc., Chicago, IL).
Results
Folic acid supplementation was reported by 3,758
women (17.2%, 95% CI = 16.2-18.2%); iron supplementa-
tion by 4,887 women (22.3%, 95%CI = 21.7-22.9%) and
3,508 women (16.1%, 95%CI = 15.5-16.5%) reported tak-
ing both supplements. The distributions of socio-
demographics, morbidity and health care utilization by
supplement use are summarized in Tables 1 and 2. Most
women were Chagga (57.9%) as were their partners
(52.1%), and most were delivering their second or later
child (60.8%), were married (89.5%), and had only pri-
mary education (61.0%). The most common occupation
among the women was housewife (25.6%), while busi-
ness (32.2%) was the most common occupation among
their partners. Nearly all women (98.9%) had received
some antenatal care during pregnancy but 26% had less
than the recommended minimum of four antenatal visits
per pregnancy. More than half (52.7%) did not knew
their HIV status, this proportion declined from around
90% percent in 2000 to six percent in 2008 when HIV
testing and anti-retroviral therapy became part of clinical
practice at KCMC [23]. The most common medical con-
ditions during pregnancy were malaria (20.4%) and
infections (40.8%).
In the multiple regression analysis with all pre-
sented variables included in the model (Table 3),
higher odds of folic acid supplement use were seen in
women aged 35 years or older (OR = 1.17, 1.02-1.34),
women from the Pare tribe (OR = 1.16, 1.02-1.32), and
housewives (OR = 1.16, 1.01-1.34). Lower odds of folic
acid supplementations were seen in women expecting
their second or later child (OR = 0.73, 0.66-0.80) and
those with few antenatal visits (OR = 0.57, 0.42-0.77
for 0–1 visits and OR= 0.72, 0.60-0.85 for 2–3 visits).
With respect to maternal health, higher odds of folic
acid supplement use were seen in women who did
not know their HIV status (OR = 1.54, 1.42-1.67), and
Table 1 Socio-demographic characteristics of pregnant women receiving folic acid and iron
Na (%) % Receiving folic acid
(n = 3,758)
Chi square
p-value
% Receiving Iron
(n = 4,887)
Chi-square
p-value
% Receiving iron+
folate (n = 3,508)
Chi square
p-value
Woman's marital status
Married 19,598 (89.5) 16.8 *** 21.9 *** 15.7 ***
Not Married 2,168 (9.9) 21.0 27.0 19.6
Woman's age
26-35 10,657 (48.7) 15.5 20.0 14.1
Under 18 475 (2.2) 22.1 26.1 21.1
18–25 8,493 (38.8) 19.3 25.4 18.3
Over 35 2,169 (9.9) 16.3 *** 20.7 *** 15.5 ***
Woman's tribe
Chagga 12,679 (57.9) 16.4 *** 21.4 *** 15.3 ***
Pare 2,543 (11.6) 20.0 25.0 18.9
Other 6,611 (30.2) 17.7 23.2 16.4
Woman’s highest educational level
None 355 (1.6) 21.7 * 27.3 21.1
Primary (1–7) 13,355 (61.0) 17.6 23.3 16.9
Secondary (8–11) 1,112 (5.1) 16.1 21.6 15.2
Higher (12+) 6,999 (32.0) 16.2 20.4 14.3
Woman's occupation
Professional 3,487 (15.9) 15.9 *** 19.6 *** 13.4 ***
Housewife 5,613 (25.6) 21.3 26.2 20.3
Farmer 3,947 (18.0) 15.3 22.1 14.7
Service 1,605 (7.3) 15.3 20.3 14.3
Business 5,033 (23.0) 15.7 20.0 15.0
Other 2,026 (9.3) 16.7 24.4 15.5
Partner's tribe
Chagga 11,408 (52.1) 16.2 *** 21.5 *** 15.1 ***
Pare 2,505 (11.4) 19.0 24.6 17.8
Other 7,774 (35.2) 18.3 23.2 17.0
Partner’s highest educational level
None 125 (0.6) 24.8 ** 32.0 24.0
Primary (1–7) 10,812 (49.4) 17.9 23.6 17.1
Secondary (8–11) 836 (3.8) 17.1 22.1 16.0
Higher (12+) 10,011 (45.7) 16.3 20.9 14.8
Partner's occupation
Professional 4,641 (21.2) 15.6 *** 19.4 *** 13.5 ***
Farmer 2,036 (9.3) 20.3 26.2 19.4
Business 7,047 (32.2) 16.1 21.3 15.0
Skilled worker 2,894 (13.2) 10.6 19.3 10.2
Other 707 (3.2) 18.8 27.2 17.3
Service 4,464 (20.4) 23.1 26.5 22.3
Northern Tanzania 1999-2008.
* p< 0.05.
** p< 0.01.
*** p< 0.001.
aThe numbers do not add to the total due to missing values.
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Table 2 Morbidity and health services usage data and percentages of pregnant women receiving folic acid and iron
Na (%) % Receiving folic acid
(n = 3,758)
Chi square
p-value
% Receiving Iron
(n= 4,887)
Chi square
p-value
% Receiving iron+
folate (n = 3,508)
Chi square
p-value
Before pregnancy
Malaria
Y 12,605 (57.6) 12.8 *** 20.4 *** 11.7 ***
N 9,284 (42.4) 23.1 25.0 21.9
Other diseases before pregnancy
Y 3,795 (17.3) 10.0 *** 19.6 *** 8.7 ***
N 18,094 (82.7) 18.7 22.9 17.6
HIV
Y 795 (3.8) 18.0 *** 26.4 ** 16.6 ***
N 11,059 (43.5) 14.8 21.5 13.4
Status unknown 10,035 (52.7) 19.7 22.9 18.9
During pregnancy
Parity
First child 8,595 (39.3) 20.3 *** 26.5 *** 18.8 ***
Not first child 13,294 (60.8) 15.1 19.6 14.2
Antenatal care during pregnancy
Y 21,658 (98.9) 17.2 *** 22.4 *** 11.9 ***
N 160 (0.7) 12.5 15.6 16.1
Number of antenatal care visits
“0-1” 502 (2.4) 14.5 * 18.5 13.1 *
“2-3” 5017 (23.6) 15.9 14.9 14.9
“4-8” 14387 (67.6) 17.6 16.4 16.4
“9-15” 1392 (6.5) 18.0 20.5 16.6
Preeclampsia/Eclampsia
Y 8881 (4.0) 10.2 *** 12.5 8.5 ***
N 21,008 (96.0) 17.5 22.7 16.3
Anaemia
Y 471 (2.2) 70.1 *** 74.9 *** 65.8 ***
N 21,418 (97.9) 16.0 21.2 14.9
Malaria
Y 4,465 (20.4) 11.1 *** 14.3 10.2 ***
N 17,424 (79.6) 18.7 24.4 17.5
Infections
Y 8,924 (40.8) 12.2 *** 15.6 10.7 ***
N 12,965 (59.2) 20.6 27.0 19.7
Other diseases during pregnancy
Y 1,074 (4.9) 11.0 *** 13.7 9.0 ***
N 20,815 (95.1) 17.5 22.8 16.4
Northern Tanzania 1999-2008.
* p< 0.05.
** p< 0.01.
*** p< 0.001.
aThe numbers do not add to the total due to missing values.
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Table 3 Associations of predictors of antenatal folic acid and iron supplementation in Northern Tanzania 1999–2008
from the multiple regression analysis
% Receiving folic acid (n = 3,758)a % Receiving Iron (n = 4,887)a % Receiving iron+ folate (n =3,508)a
Adjustedb OR (95% CI) Adjustedb OR (95% CI) Adjustedb OR (95%CI)
Woman's marital status
Married 1 1 1
Not Married 1.14(1.01–1.28)* 1.14 (0.99–1.29) 1.14 (1.00–1.29)
Woman's age
26-35 1 1 1
Under 26 1.02 (0.93-1.12) 1.05 (0.96–1.16) 1.05 (0.96-1.16)
Over 35 1.17 (1.02-1.34)* 1.25 (1.08–1.43)* 1.25 (1.08-1.43)**
Woman's tribe
Chagga 1 1 1
Pare 1.16 (1.02-1.32)* 1.16 (1.01-1.32)* 1.16 (1.01-1.32)*
Other 1.00 (0.91-1.10) 0.99 (0.89-1.09) 0.99 (0.89-1.09)
Woman’s highest education level
None 1.29 (0.96-1.74) 1.34 (0.99-1.81) 1.34 (0.99-1.81)
Primary (1–7) 1.02 (0.92-1.13) 1.05 (0.95-1.16) 1.05 (0.95-1.16)
Secondary (8–11)/Higher (12+) 1 1 1
Woman's occupation
Professional 1 1 1
Housewife 1.16 (1.01-1.34)* 1.28 (1.10-1.49)** 1.28 (1.10-1.49)**
Other 0.88 (0.77-1.01) 0.96 (0.94-1.14) 0.96 (0.84-1.11)
Partner's tribe
Chagga 1 1 1
Pare 1.13 (0.99-1.29) 1.13 (0.99-1.30) 1.13 (0.99-1.30)
Other 1.04 (0.95-1.14) 1.03 (0.94-1.14) 1.03 (0.94-1.14)
Partner’s highest education level
None 1.29 (0.80-2.08) 1.27 (0.78-2.07) 1.27 (0.78-2.07)
Primary (1–7) 1.09 (0.99-1.19) 1.08 (0.98-1.18) 1.08 (0.98-1.18)
Secondary (8–11)/Higher (12+) 1 1 1
Partner's occupation
Professional 1 1 1
Skilled worker 0.67 (0.56-0.79)*** 0.72 (0.61-0.86) 0.72 (0.61-0.86)***
Other 1.13 (1.01-1.26)* 1.20 (1.06-1.35)* 1.20 (1.06-1.35)**
Before Pregnancy
Malaria
Y 0.57 (0.53-0.62)*** 0.55 (0.51-0.60)*** 0.55 (0.50-0.60)***
N 1 1 1
Other diseases before pregnancyc
Y 0.62 (0.55-0.70)*** 0.58 (0.51-0.66)*** 0.58 (0.51-0.66)***
N 1 1 1
Maternal HIV
Y 1.30 (1.06-1.59)* 1.31 (1.06-1.62)* 1.31 (1.06-1.62)*
N 1 1 1
Status unknown 1.54 (1.42-1.67)*** 1.63 (1.50-1.76)*** 1.63 (1.50-1.76)***
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Table 3 Associations of predictors of antenatal folic acid and iron supplementation in Northern Tanzania 1999–2008
from the multiple regression analysis (Continued)
During pregnancy
Parity
First Child 1 1 1
Not first child 0.73 (0.66-0.80)*** 0.75 (0.68-0.82)*** 0.75 (0.68-0.82)***
Number of antenatal care visits
“0-1” 0.57 (0.42-0.77)*** 0.60 (0.45-0.70)*** 0.60 (0.45-0.79)**
"2-3" 0.72 (0.60-0.85)*** 0.80 (0.72-0.88)*** 0.80 (0.72-0.88)**
“4-8” 0.88 (0.76-1.03) 1.13 (0.97-1.33) 1.13 (0.97-1.33)
"9-15" 1 1 1
Preeclampsia & Eclampsia
Y 0.48 (0.38-0.61)*** 0.42 (0.33-0.54)*** 0.42 (0.33-0.54)***
N 1 1 1
Anemia
Y 12.03 (9.66-14.98)*** 10.81 (8.72-13.39)*** 10.81 (8.72-13.39)***
N 1 1 1
Malaria
Y 0.45 (0.41-0.51)*** 0.44 (0.40-0.50)*** 0.44 (0.40-0.50)***
N 1 1 1
Infections
Y 0.45 (0.42-0.49)*** 0.41 (0.37-0.44)*** 0.41 (0.37-0.44)***
N 1 1 1
Other diseases during pregnancyc
Y 0.55 (0.44-0.69)*** 0.46 (0.36-0.59)*** 0.46 (0.36-0.59)***
N 1 1 1
a Number included in the multiple regression model is 21,027 (862 observations had one or more missing values).
b All variables are in the adjusted model.
c “Other diseases before pregnancy” included diabetes, heart disease, epilepsy, liver disease, sickle cell, TB, and lung disease. “Other diseases during pregnancy”
included gestational diabetes, tuberculosis, diabetes, hypertension, epilepsy, bleeding, jaundice, schistosomiasis, heart disease and lung disease.
* p≤ 0.05.
** p≤0.01.
*** p≤ 0.001.
Ogundipe et al. BMC Public Health 2012, 12:481 Page 7 of 10
http://www.biomedcentral.com/1471-2458/12/481women who had anaemia during pregnancy (OR =
12.03, 9.66-15.0), whereas other medical conditions
before or during pregnancy were associated with
lower odds of folic acid supplement use; malaria be-
fore pregnancy (OR = 0.57, 0.53-0.62), malaria during
pregnancy (OR = 0.45, 0.41-0.51), infectious diseases
(OR = 0.45, 0.42-0.49), preeclampsia/eclampsia (OR =
0.48, 0.38-0.61), or other diseases during pregnancy
(OR = 0.55, 0.44-0.69). Similar patterns of associations
were seen for iron and iron/folic acid supplementa-
tion, results for these outcomes are presented in the
tables. There was no trend in supplementation with
folic acid or iron according to period of birth (1999–
2004 vs. 2005–2008), and inclusion of year of birth in
the multiple regression analysis did not change the
results.Discussion
Our key finding was that despite the WHO recommen-
dations and the high occurrence of adverse health condi-
tions and birth outcomes, only one fifth of the pregnant
women visiting KCMC report using iron or folic acid
supplements during pregnancy. Remarkably, women
with morbidity were less likely to be prescribed or use
folic acid and iron supplements. The proportion of
women reporting supplementation with folate and/or
iron is lower than what has been found in developed
countries. Countries such as the USA, Norway, and the
Netherlands report folic acid supplementation among
pregnant women at 43%, 35%, and 72.4%, respectively
[2,4,9]. Typically, iron supplementation is higher than
folic acid supplementation. In the USA and the Nether-
lands iron supplementation among pregnant women is
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tries, iron supplementation during pregnancy is as high
as 70% in the Philippines and 69% in Senegal [20,21].
Our finding of decreased supplementation among
women with co-morbidities (other than anaemia), also
after accounting for number of antenatal visits in the
adjusted analyses, contrast with other studies where
women with co-morbidities are more likely to use folic
acid and iron supplements during pregnancy [16-18].
However, these other studies were conducted in devel-
oped countries where diagnosis is almost always tied to
treatment and where women who are recognized as hav-
ing co-morbidities during pregnancy tend to receive
more intensive antenatal care. This may not be the case
in Northern Tanzania where the presence of chronic and
infectious diseases could be an indicator of poor access
to health care, a factor which also contributes to lower
utilization of antenatal care services and thus use of folic
acid and iron supplements. This explanation is sup-
ported by our findings that women who have more ANC
visits have significantly greater odds of using folic acid
and both folic acid and iron supplements. Similar results
have been found in previous studies [5,20].
The WHO estimates that, globally, 41% of women suf-
fer from anemia as result of iron deficiency resulting
from low supplementation [24]. Provision of folic acid
and iron supplements, in addition to a standard weekly
dose of prophylactic chloroquine for malaria prophy-
laxis, dramatically reduced the prevalence of anaemia
during pregnancy in a prospective intervention study of
1045 women in two antenatal clinics in Dar Es Salaam
[13]. However, factors associated with intake of these
supplements are unclear, and may be setting-specific. In
a study from Senegal, iron supplementation adherence
was increased in women who were offered free access to
supplements compared to women who only received a
prescription (86% vs. 49%). Counselling on the health
benefits of supplementation significantly increased com-
pliance among the Senegalese [21]. In our study sample,
the proportion receiving supplementation was low des-
pite a very high rate of attendance to antenatal clinics –
these clinic visits presumably included counselling. Be-
cause folic acid and iron are prescribed and dispensed
with a very low co-payment (US$ 0.25 per monthly
dose), the low use of supplementation, may be a result
of a lack of knowledge about the benefits of supplemen-
tation rather than non-availability. Interventions involv-
ing educating health care providers and ensuring
availability of folic acid and iron have been shown to im-
prove intake, as evidenced by a precipitous decrease in
prevalence of anemia during the course of pregnancy in
a population where provider-education was given [13].
Notably, primiparous women with anaemia during
pregnancy were also found to have significantly greaterodds of using any supplements than multiparous
women. This is a consistent finding in studies that have
considered parity as a predictive factor for folic acid and
iron supplementation [7,19-21,25,26]. The common ex-
planation for finding is that multiparous women may
have a more casual attitude to supplementation espe-
cially if they have had uncomplicated pregnancies in the
past.
The definition of anaemia (haemoglobin less than
8.5 g/dl) in the birth registry corresponds with national
criteria which are applied at antenatal clinics for referral
and further investigation. However, since prevalence
estimates for anaemia usually include all individuals with
haemoglobin less than 11 g/dl, which includes less se-
vere anaemia, it is difficult to compare the prevalence
seen in our study sample to the prevalence for the whole
country [12]. In a well designed study of 2235 pregnant
women in the Dar Es Salaam region, 60% were anaemic
and 2.2% severely anaemic at the first booking [13]. An
earlier study investigating haemoglobin concentrations
in pregnant women in the Moshi area also showed a
high prevalence of anaemia [27]. The WHO bases its
recommendations for folic acid and iron supplementa-
tion mostly on data from women with anaemia defined
as haemoglobin less than 11 g/dl, and the presence of
anaemia, based solely on haemoglobin level, is the main
indication for folic acid and iron supplementation [4].
Although hemoglobin is measured at antenatal visits,
supplementation is mainly based on clinical signs of an-
aemia and not haemoglobin level specifically (personal
communication). Increasing supplementation in this re-
gion will require antenatal care clinics at KCMC and
elsewhere to reconsider their definition of anaemia to
make it consistent with the WHO definition and use
these criteria for prescribing and dispensing iron and
folic acid supplements.
While it is clear that women with HIV will especially
benefit from folic acid and iron supplementation [25],
our study showed that women with unknown HIV status
were more likely to use both iron and folic acid supple-
ments. For women in Northern Tanzania, and perhaps
other developing countries, special attention needs to be
paid to providing supplements to women with chronic
and infectious diseases prior to and during pregnancy.
Only in the case of malaria prophylaxis with sulfadoxine-
pyrimethamine should special consideration be given in the
administration of folic acid as it reduces the efficacy of sul-
fadoxine as an antimalarial [26].
A major strength of this study is the large sample size.
Another strength is the method of data collection
through a comprehensive birth registry. The birth regis-
try data were carefully collected and comprise informa-
tion obtained from questionnaire based interviews done
by designated midwives and women’s medical records.
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A limitation of this study is that the coverage of births
in the KCMC region in not complete. It is estimated that
29% of births in the KCMC catchment region occur at
home [12]. KCMC is not primarily a referral hospital but
also serves as a local hospital for the area, and the ethnic
and socio-demographic composition of the women who
deliver at KCMC is diverse. However, because of its’ sta-
tus as a referral hospital, women who deliver at KCMC
may represent a somewhat more privileged group than
those who deliver at home or at local hospitals in the
area. In order to obtain a more population based sample
we excluded women who were referred for delivery at
KCMC due to complications. A second limitation is the
fact that health conditions were based on self-reports
with supplementary information from medical records.
Some of the medical diagnoses were not established by
diagnostic tests and may thus be over or underestimated
in this sample. A third limitation of this secondary data
analysis is the availability of only dichotomous data for
characterizing outcomes, as timing and frequency of use
of folic acid or iron supplements was not available.
Conclusions
The use of folic acid and iron supplementation for preg-
nant women in Northern Tanzania is low and does not
meet WHO recommendations for the treatment of an-
aemia during pregnancy, despite the high number of
antenatal care visits per participant. Socio-demographic
factors including maternal age, occupation and partners’
occupation, maternal characteristics including parity and
co-morbidities, and healthcare factors such as HIV test-
ing, few ANC visits, infections and chronic diseases are
all significantly associated with supplementation. A sys-
tematic audit of the screening and supplementation sys-
tem for pregnant women at KCMC and in the region
may reveal reasons for this low use. Following up our
findings, further studies should consider the effects of
involving the women’s partners, and developing inter-
ventions especially targeting women at increased risk in
clinic. Education of health care providers, routine coun-
selling as part of the antenatal care, follow up of adher-
ence among women at risk, and routines to ensure
supplies of supplements at distribution points, represent
potential actions to improve micronutrient status of
pregnant women in Tanzania.
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